Top

Published in:

01-02-2014 | Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)

Nephropathy in Youth and Young Adults with Type 2 Diabetes

Authors: Carolina Solis-Herrera, Curtis L. Triplitt, Jane L. Lynch

Published in: Current Diabetes Reports | Issue 2/2014

Abstract

The occurrence and progression of nephropathy associated with early onset type 2 diabetes (T2D) is a consequence of the ongoing epidemic of childhood obesity. Minimal evidence regarding treatment effectiveness of renovascular comorbidities in youth with early onset T2D is available, due to the relatively recent emergence of T2D in youth and young adults. Extrapolation of adult therapy guidelines is not an ideal approach to making therapeutic decisions in this population. Evolving management and intervention strategies are based on accumulating longitudinal data from cohorts of well characterized youth and young adults with T2D. The degree of similarity in histologic findings and disease specific characteristics of kidney disease in patients with early onset T2D and albuminuria compared with affected adults is not well characterized. Early aggressive therapies to minimize the impact of nephropathy are indicated as the evidence for best therapies in youth with T2D are further explored.

1.•

Alleyn CR, Volkening LK, Wolfson J, et al. Occurrence of microalbuminuria in young people with type 1 diabetes: importance of age and diabetes duration. Diabet Med. 2010;27:532–7. doi:10.1111/j.1464-5491.2010.02983.x. Comparison of clinical MA occurrence data for children with type 1 and type 2 diabetes in a clinical setting. PubMedCentralPubMedCrossRef

Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300–6. doi:10.2337/dc05-2470.PubMedCrossRef

Kiess W, Bottner A, Bluher S, et al. Type 2 diabetes mellitus in children and adolescents—the beginning of a renal catastrophe? Nephrol Dial Transplant. 2004;19:2693–6. doi:10.1093/ndt/gfh455.

Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99–111.CrossRef

5.••

TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735–41. doi:10.2337/dc12-2420. Recent data from the TODAY study cohort specific to the factors associated with early findings of hypertension and MA in youth and young adults with T2D. CrossRef

Marcovecchio ML, Dalton RN, Chiarelli F, et al. A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care. 2011;34:1011–3. doi:10.2337/dc10-2028.PubMedCrossRef

Yokoyama H, Okudaira M, Otani T, et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care. 1998;21:1080–5.PubMedCrossRef

8.•

Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010;157:245–251.e1. doi:10.1016/j.jpeds.2010.02.021. The characteristics of youth with type 1, type 2 and other forms of diabetes are described in regard to blood pressure observations. PubMedCrossRef

Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20:844–7.PubMedCrossRef

10.

TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013;36:1749–57. doi:10.2337/dc12-2393.CrossRef

11.•

D’Adamo E, Caprio S. Type 2 diabetes in youth: Epidemiology and Pathophysiology. Diabetes Care. 2011;34(Suppl 2):S161–5. doi:10.2337/dc11-s212. Visceral fat accumulation in obese children with a family history of T2D are at risk for accelerated glucose homeostasis dysregulation and β-cell function decline.

12.

Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315:215–9. doi:10.1056/NEJM198607243150402.PubMedCrossRef

13.

Barkai L, Vamosi I, Lukacs K. Enhanced progression of urinary albumin excretion in IDDM during puberty. Diabetes Care. 1998;21:1019–23.PubMedCrossRef

14.

Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008;336:697–701. doi:10.1136/bmj.39478.378241.BE.PubMedCrossRef

15.

Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes. 2007;8 Suppl 9:16–27. doi:10.1111/j.1399-5448.2007.00330.x.PubMedCrossRef

16.

Linder BL, Fradkin JE, Rodgers GP. The TODAY Study: an NIH perspective on its implications for research. Diabetes Care. 2013;36:1775–6. doi:10.2337/dc13-0707.PubMedCrossRef

17.

Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177–88.CrossRef

18.

Bryden KS, Dunger DB, Mayou RA, et al. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26:1052–7.PubMedCrossRef

19.

White NH, Cleary PA, Dahms W, et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804–12.PubMedCrossRef

20.

Rosenbloom AL, Silverstein JH, Amemiya S, et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:17–32. doi:10.1111/j.1399-5448.2009.00584.x.PubMedCrossRef

21.

SEARCH Study Group. SEARCH for Diabetes in Youth: a multi-center study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials. 2004;25:458–71. doi:10.1016/j.cct.2004.08.002.CrossRef

22.

Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700. doi:10.1016/j.jpeds.2004.12.042.PubMedCrossRef

23.

Dabelea D, Bell RA, et al. Writing group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–24. doi:10.1001/jama.297.24.2716.PubMedCrossRef

24.

Svensson M, Sundkvist G, Arnqvist HJ, et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:2903–9.PubMedCrossRef

25.•

TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56. doi:10.1056/NEJMoa1109333. This is the primary outcome paper describing the significant differences between 3 treatment arms of therapy for newly diagnosed youth with T2D and their comorbidities over an average of 6.5 years in the study. PubMedCrossRef

26.

TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758–64. doi:10.2337/dc12-2388.CrossRef

27.

Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97:59–74. doi:10.1016/j.mcna.2012.10.010.PubMedCentralPubMedCrossRef

28.

Tsioufis C, Dimitriadis K, Antoniadis D, et al. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens. 2004;17:470–6. doi:10.1016/j.amjhyper.2004.02.008.PubMedCrossRef

29.

Wadwa RP, Urbina EM, Anderson AM, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2010;33:881–6. doi:10.2337/dc09-0747.PubMedCrossRef

30.

May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics. 2012;129:1035–41. doi:10.1542/peds.2011-1082.PubMedCrossRef

31.•

Peters A, Laffel L, American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care. 2011;34:2477–85. doi:10.2337/dc11-1723. This article discusses the challenges of transition of care when treating the adolescent with T2D. PubMedCrossRef

32.

Anderson BJ, Edelstein S, Abramson NW, et al. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care. 2011;34:2205–7. doi:10.2337/dc11-0431.PubMedCrossRef

33.

Nathan DM, Zinman B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307–16.PubMedCentralPubMedCrossRef

34.

Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55:1463–9.PubMedCrossRef

35.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86. doi:10.1056/NEJM199309303291401.

36.

DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76. doi:10.1056/NEJMoa1111732.PubMedCrossRef

37.

Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30:2593–8. doi:10.2337/dc07-0450.PubMedCrossRef

38.

Bogdanovic R. Diabetic nephropathy in children and adolescents. Pediatr Nephrol. 2008;23:507–25. doi:10.1007/s00467-007-0583-2.PubMedCrossRef

39.

Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302–11. doi:10.1046/j.1523-1755.2000.00166.x.PubMedCrossRef

40.

Eppens MC, Craig ME, Jones TW, et al. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care, and complications. Curr Med Res Opin. 2006;22:1013–20. doi:10.1185/030079906X104795.PubMedCrossRef

41.

Kim NH, Pavkov ME, Knowler WC, et al. Predictive value of albuminuria in American Indian youth with or without type 2 diabetes. Pediatrics. 2010;125:e844–51. doi:10.1542/peds.2009-1230.PubMedCentralPubMedCrossRef

42.

Pavkov ME, Hanson RL, Knowler WC, et al. Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care. 2007;30:1758–63. doi:10.2337/dc06-2010.PubMedCrossRef

43.

Pavkov ME, Bennett PH, Knowler WC, et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296:421–6. doi:10.1001/jama.296.4.421.PubMedCrossRef

44.•

Dart AB, Sellers EA, Martens PJ, et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012;35:1265–71. doi:10.2337/dc11-2312. ICD code based review of 1353 youth with diabetes and a control group to determine the long term renovascular outcomes in first nation Canadian youth. These T2D youths had a 23-fold increased risk for renal failure and a 39-fold increased risk for dialysis when compared with control subjects and a 4-fold increase in renal failure compared with T1D youth. PubMedCrossRef

45.

Dean H. NIDDM-Y in First Nation children in Canada. Clin Pediatr. 1998;37:89–96.CrossRef

46.

Sellers EA, Blydt-Hansen TD, Dean HJ, et al. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. Diabetes Care. 2009;32:786–90. doi:10.2337/dc08-1828.PubMedCrossRef

47.

Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–8. doi:10.2337/dc11-2189.PubMedCrossRef

48.

Tsioufis C, Mazaraki A, Dimitriadis K, et al. Microalbuminuria in the paediatric age: current knowledge and emerging questions. Acta Paediatr. 2011;100:1180–4. doi:10.1111/j.1651-2227.2011.02291.x.PubMedCrossRef

49.

Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369:1823–31. doi:10.1016/S0140-6736(07)60821-6.PubMedCrossRef

50.

Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26:2999–3005.PubMedCrossRef

51.

Ettinger LM, Freeman K, DiMartino-Nardi JR, et al. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. J Pediatr. 2005;147:67–73. doi:10.1016/j.jpeds.2005.02.003.PubMedCrossRef

52.

Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67. doi:10.1210/jc.2010-1642.PubMedCrossRef

53.•

Savino A, Pelliccia P, Chiarelli F, et al. Obesity-related renal injury in childhood. Horm Res Paediatr. 2010;73:303–11. doi:10.1159/000308161. This article review the association between obesity and the risk of kidney disease with regard to childhood.PubMedCrossRef

54.•

Ritz E, Koleganova N, Piecha G. Is there an obesity-metabolic syndrome related glomerulopathy? Curr Opin Nephrol Hypertens. 2011;20:44–9. doi:10.1097/MNH.0b013e3283414ca1. There is evidence for a focal segmental glomerosclerosis related to obesity as well as a likely aggravation of most primary kidney disease in the obese patient. PubMedCrossRef

55.

Burgert TS, Dziura J, Yeckel C, et al. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. Int J Obes. 2006;30:273–80. doi:10.1038/sj.ijo.0803136.CrossRef

56.

Schultz CJ, Konopelska-Bahu T, Dalton RN, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999;22:495–502.PubMedCrossRef

57.

Olsen BS, Sjolie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18:160–4. doi:10.1016/S1056-8727(03)00073-4.PubMedCrossRef

58.

Doublier S, Lupia E, Catanuto P, et al. Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev. 2011;7:28–34.PubMedCrossRef

59.

Bangstad HJ, Dahl-Jorgensen K, Kjaersgaard P, et al. Urinary albumin excretion rate and puberty in non-diabetic children and adolescents. Acta Paediatr. 1993;82:857–62.PubMed

60.

Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. 2008;25 Suppl 2:25–9. doi:10.1111/j.1464-5491.2008.02496.x.PubMedCrossRef

61.

ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. doi:10.1056/NEJMoa0802987.PubMedCrossRef

62.

Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172:761–9. doi:10.1001/archinternmed.2011.2230.PubMedCentralPubMedCrossRef

63.•

James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2013. Published online December 18, 2013. doi:10.1001/jama.2013.284427. This evidence-based document provides an updated analysis of current evidence regarding BP treatment thresholds, goals, and drug treatment strategies focused on date for adults above age 18 years of age.

64.

Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8. doi:10.1001/jama.2010.884.PubMedCentralPubMedCrossRef

65.

Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719–26. doi:10.1016/j.amjmed.2010.02.014.PubMedCentralPubMedCrossRef

66.

Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170–9. doi:10.1681/ASN.2004090763.PubMedCrossRef

67.

Rhodes ET, Prosser LA, Hoerger TJ, et al. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med. 2012;29:453–63. doi:10.1111/j.1464-5491.2011.03542.x.PubMedCrossRef

68.

Yusuf S, Teo KK, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.PubMedCrossRef

69.

Hermida RC, Ayala DE, Mojon A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313–21. doi:10.1681/ASN.2011040361.PubMedCrossRef

70.

Urbina EM, Kimball TR, Khoury PR, et al. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens. 2010;28:1692–8. doi:10.1097/HJH.0b013e32833a6132.PubMedCentralPubMedCrossRef

71.

Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. QJM. 2009;102:799–806. doi:10.1093/qjmed/hcp121.PubMedCrossRef

72.

Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48:17–26. doi:10.1007/s00125-004-1599-9.PubMedCrossRef

73.

Toto RD. Lessons from the African-American Study of kidney disease and hypertension: an update. Curr Hypertens Rep. 2006;8:409–12.PubMedCrossRef

74.

Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef

75.

Rahman M, Douglas JG, Wright Jr JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125–44.PubMedCrossRef

76.

Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91. doi:10.1056/NEJMoa0706245.PubMedCrossRef

77.•

Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131:364–82. doi:10.1542/peds.2012-3494. Clinical practice guideline for evidence based care for youth and young adults with type 2 Diabetes. This guideline underwent peer review and is endorsed by the Academy of Pediatrics. PubMedCrossRef

78.••

Dart AB, Sellers EA, Dean HJ. Kidney disease and youth onset type 2 diabetes: considerations for the general practitioner. Int J Pediatr. 2012;2012:237360. doi:10.1155/2012/237360. Practical clinical advice for management of renovascular complications in youth onset T2D..PubMedCentralPubMedCrossRef

79.

Davis CL. Undetected hypertension and prehypertension in children with diabetes need attention. J Pediatr. 2010;157:182–4. doi:10.1016/j.jpeds.2010.04.022.PubMedCrossRef

80.

Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874–9. doi:10.1001/jama.298.8.874.PubMedCrossRef

81.

Flynn J. The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol. 2013;28:1059–66. doi:10.1007/s00467-012-2344-0.PubMedCrossRef

82.

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.CrossRef

83.

Bell DS. Hypertension and diabetes: a toxic combination. Endocr Pract. 2008;14:1031–9.PubMedCrossRef

84.

Bakris G, Vassalotti J, Ritz E, et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010;78:726–36. doi:10.1038/ki.2010.292.PubMedCrossRef

85.

Springer SC, Silverstein J, Copeland K, et al. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013;131:e648–64. doi:10.1542/peds.2012-3496.PubMedCrossRef

86.

Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993;22:188–95.PubMed

87.

Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9.PubMedCrossRef

88.

Marcovecchio ML, Tossavainen PH, Dunger DB. Status and rationale of renoprotection studies in adolescents with type 1 diabetes. Pediatr Diabetes. 2009;10:347–55. doi:10.1111/j.1399-5448.2009.00510.x.PubMedCrossRef

89.

Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–93. doi:10.1056/NEJMoa021835.PubMedCrossRef

90.

Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care. 2011;34:424–9. doi:10.2337/dc10-1177.PubMedCrossRef

91.

Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32. doi:10.1046/j.1523-1755.2003.00712.x.PubMedCrossRef

92.

Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–76.PubMedCrossRef

93.

Hill JO, Galloway JM, Goley A, et al. Scientific statement: socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care. 2013. doi:10.2337/dc13–1161.

94.

Kawahara R, Amemiya T, Yoshino M, et al. Dropout of young non-insulin-dependent diabetics from diabetic care. Diabetes Res Clin Pract. 1994;24:181–5.PubMedCrossRef

95.

de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.PubMed

96.

Le-Ha C, Beilin LJ, Burrows S, et al. Oral contraceptive use in girls and alcohol consumption in boys are associated with increased blood pressure in late adolescence. Eur J Prev Cardiol. 2012. doi:10.1177/2047487312452966.PubMed

97.

Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care. 2009;32:38–44. doi:10.2337/dc08-1526.PubMedCrossRef

98.

Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–51. doi:10.1056/NEJMoa055202.PubMedCrossRef

99.

Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr. 2011;5:137–42. doi:10.1016/j.dsx.2012.02.013.PubMedCrossRef

100.

Mathiesen ER, Ringholm L, Feldt-Rasmussen B, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy—the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012;7:2081–8. doi:10.2215/CJN.00920112.PubMedCrossRef

Title: Nephropathy in Youth and Young Adults with Type 2 Diabetes
Authors: Carolina Solis-Herrera
Curtis L. Triplitt
Jane L. Lynch
Publication date: 01-02-2014
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 2/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-013-0456-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Impact of Breastfeeding on Maternal Metabolism: Implications for Women with Gestational Diabetes

Metabolic Basis of Ethnic Differences in Diabetes Risk in Overweight and Obese Youth

Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus

Perinatal Outcomes in Type 2 Diabetes

Implementing Community-Based Diabetes Programs: The Scripps Whittier Diabetes Institute Experience

Inpatient Management of Women with Gestational and Pregestational Diabetes in Pregnancy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage